Sign In
Buy PTGX
$95.41
+2.18 (+2.34%)
At Close: Jun 03, 2026
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the P
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
07:05am, Wednesday, 21'st May 2025
NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
07:30pm, Tuesday, 06'th May 2025
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to earnings of $3.26 per share a year ago.
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 06'th May 2025
Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st Conference call
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
10:35am, Wednesday, 23'rd Apr 2025
NEWARK, CA / ACCESS Newswire / April 23, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that an abstract was accepted for presentation at the Plenary Session at the A
Protagonist Therapeutics Reports Granting of Inducement Award
04:05pm, Wednesday, 16'th Apr 2025
NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
10:55am, Tuesday, 25'th Mar 2025
The consensus price target hints at a 27.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
07:00am, Tuesday, 18'th Mar 2025
Past Winners include Waymo, Nvidia, Duolingo, and Novo Nordisk, among others NEWARK, CA / ACCESS Newswire / March 18, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why
01:01pm, Wednesday, 12'th Mar 2025
Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It
04:00pm, Tuesday, 11'th Mar 2025
Protagonist Therapeutics, Inc. achieved primary endpoint in a phase 3 VERIFY study using rusfertide in polycythemia vera and the phase 2b ANTHEM-UC study using icotrokinra in ulcerative colitis. Icotr
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
01:20pm, Tuesday, 11'th Mar 2025
The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.
Overlooked Stock: PTGX
04:57pm, Monday, 10'th Mar 2025
Protagonist Therapeutics (PTGX) rallied 45% after its latest drug trial to treat people with active ulcerative colitis saw success. George Tsilis says there's more positive catalysts behind the stock,
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
10:19am, Monday, 10'th Mar 2025
Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study. The post Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
10:04am, Monday, 10'th Mar 2025
On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active ulcerative colitis (UC).
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline resu
